47 related articles for article (PubMed ID: 38578876)
41. Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy.
Molinelli C; Parisi F; Razeti MG; Arecco L; Cosso M; Fregatti P; Del Mastro L; Poggio F; Lambertini M
Expert Rev Anticancer Ther; 2021 Mar; 21(3):241-250. PubMed ID: 33245671
[No Abstract] [Full Text] [Related]
42. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
[TBL] [Abstract][Full Text] [Related]
43. Telangiectasias induced by combination tucatinib and ado-trastuzumab emtansine in a patient with metastatic breast cancer.
Rodriguez GF; Shah A; Maderal AD
Breast Dis; 2024; 43(1):61-64. PubMed ID: 38578876
[TBL] [Abstract][Full Text] [Related]
44. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Tesch ME; Gelmon KA
Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
[TBL] [Abstract][Full Text] [Related]
46. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
47. Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021.
McAndrew NP
Curr Opin Obstet Gynecol; 2022 Feb; 34(1):41-45. PubMed ID: 34967814
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
